Literature DB >> 27406986

Concepts to Target MYC in Pancreatic Cancer.

Matthias Wirth1, Siavosh Mahboobi2, Oliver H Krämer3, Günter Schneider4.   

Abstract

Current data suggest that MYC is an important signaling hub and driver in pancreatic ductal adenocarcinoma (PDAC), a tumor entity with a strikingly poor prognosis. No targeted therapies with a meaningful clinical impact were successfully developed against PDAC so far. This points to the need to establish novel concepts targeting the relevant drivers of PDAC, like KRAS or MYC. Here, we discuss recent developments of direct or indirect MYC inhibitors and their potential mode of action in PDAC. Mol Cancer Ther; 15(8); 1792-8. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27406986     DOI： 10.1158/1535-7163.MCT-16-0050

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN： 1535-7163            Impact factor:   6.261


  31 in total

1.  Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer.

Authors:  Yi Qin; Qiangsheng Hu; Shunrong Ji; Jin Xu; Weixing Dai; Wensheng Liu; Wenyan Xu; Qiqing Sun; Zheng Zhang; Quanxing Ni; Xianjun Yu; Bo Zhang; Xiaowu Xu
Journal:  Cell Prolif       Date:  2019-04-01       Impact factor: 6.831

Review 2.  Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis-A connection to licensing nodes.

Authors:  Christian Schneeweis; Matthias Wirth; Dieter Saur; Maximilian Reichert; Günter Schneider
Journal:  Small GTPases       Date:  2017-01-20

3.  RING-finger protein 6 enhances c-Myc-mediated Warburg effect by promoting MAD1 degradation to facilitate pancreatic cancer metastasis.

Authors:  Yumin Qiu; Hengqing Zhu; Debin Xu; Qian Feng; Chongyu Wen; Yunyan Du; Mingfeng Xiang; Leifeng Chen; Xiaogang Peng
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

4.  HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer.

Authors:  N Stojanovic; Z Hassan; M Wirth; P Wenzel; M Beyer; C Schäfer; P Brand; A Kroemer; R H Stauber; R M Schmid; A Arlt; A Sellmer; S Mahboobi; R Rad; M Reichert; D Saur; O H Krämer; G Schneider
Journal:  Oncogene       Date:  2016-10-10       Impact factor: 9.867

Review 5.  Harnessing metabolic dependencies in pancreatic cancers.

Authors:  Joel Encarnación-Rosado; Alec C Kimmelman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-03-19       Impact factor: 46.802

6.  A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma.

Authors:  Akimasa Hayashi; Jun Fan; Ruoyao Chen; Yu-Jui Ho; Alvin P Makohon-Moore; Nicolas Lecomte; Yi Zhong; Jungeui Hong; Jinlong Huang; Hitomi Sakamoto; Marc A Attiyeh; Zachary A Kohutek; Lance Zhang; Aida Boumiza; Rajya Kappagantula; Priscilla Baez; Jessica Bai; Marta Lisi; Kalyani Chadalavada; Jerry P Melchor; Winston Wong; Gouri J Nanjangud; Olca Basturk; Eileen M O'Reilly; David S Klimstra; Ralph H Hruban; Laura D Wood; Michael Overholtzer; Christine A Iacobuzio-Donahue
Journal:  Nat Cancer       Date:  2020-01-13

7.  Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype.

Authors:  Felix Orben; Katharina Lankes; Christian Schneeweis; Zonera Hassan; Hannah Jakubowsky; Lukas Krauß; Fabio Boniolo; Carolin Schneider; Arlett Schäfer; Janine Murr; Christoph Schlag; Bo Kong; Rupert Öllinger; Chengdong Wang; Georg Beyer; Ujjwal M Mahajan; Yonggan Xue; Julia Mayerle; Roland M Schmid; Bernhard Kuster; Roland Rad; Christian J Braun; Matthias Wirth; Maximilian Reichert; Dieter Saur; Günter Schneider
Journal:  JCI Insight       Date:  2022-05-23

8.  Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression.

Authors:  S Mazher Hussain; Rita G Kansal; Marcus A Alvarez; T J Hollingsworth; Abul Elahi; Gustavo Miranda-Carboni; Leah E Hendrick; Ajeeth K Pingili; Lorraine M Albritton; Paxton V Dickson; Jeremiah L Deneve; Danny Yakoub; D Neil Hayes; Michio Kurosu; David Shibata; Liza Makowski; Evan S Glazer
Journal:  Cell Oncol (Dordr)       Date:  2021-03-10       Impact factor: 6.730

9.  CRABP-II enhances pancreatic cancer cell migration and invasion by stabilizing interleukin 8 expression.

Authors:  Shuiliang Yu; Neetha Parameswaran; Ming Li; Yiwei Wang; Mark W Jackson; Huiping Liu; Wei Xin; Lan Zhou
Journal:  Oncotarget       Date:  2016-12-26

10.  BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC.

Authors:  Toni Jauset; Daniel Massó-Vallés; Sandra Martínez-Martín; Marie-Eve Beaulieu; Laia Foradada; Francesco Paolo Fiorentino; Jun Yokota; Bernard Haendler; Stephan Siegel; Jonathan R Whitfield; Laura Soucek
Journal:  Oncotarget       Date:  2018-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.